Results 201 to 210 of about 1,028,185 (295)

ctDNA-based detection of residual disease: implications for management of non-metastatic NSCLC. [PDF]

Front Oncol
Leclercq C, Wespiser M, Tachon G, Buisson A, Pérol M, Swalduz A.   +5 more
europepmc   +1 more source

SPHINX31 acts as a SRPK1 inhibitor targeting the ATR/DNA‐PKcs/CHK1 replicative checkpoint to inhibit cell growth in non‐small cell lung cancer

Molecular Oncology, EarlyView.
The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim, Aurelie Genoux, Nadiia Zubchuk, Haoyang Zheng, Perla Salameh, Theo Ziegelmeyer, Fabien Dalonneau, Margot Rouchette, Christiane Oddou, Simona Miron, Helene Polveche, Adiilah Mamode Cassim, Carmen Garrido, Eleni Nikolakaki, Didier Auboeuf, Tao Jia, Sophie Zinn‐Justin, Beatrice Eymin   +17 more
wiley   +1 more source

Lactate in acute kidney injury: pathobiology, risk stratification, and clinical interpretation. [PDF]

Ren Fail
Sun S, Han Z.
europepmc   +1 more source

Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation

Molecular Oncology, EarlyView.
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim, Alvin Kunyao Guo, Yoko Itahana, Srinivasaraghavan Kannan, Valerie Goh, Mingmin Ong, Terina Yan Wen Tay, Weiying Ye, Sabhashina Radha Krishnan, Jun Nishiyama, Chandra S Verma, Koji Itahana   +11 more
wiley   +1 more source

Consolidation Therapy Based on Mutation Clearance in Acute Myeloid Leukemia. [PDF]

NEJM Evid
Jacoby MA, Spencer DH, Gao F, Uy GL, Burton T, Heath SE, Du F, O'Laughlin M, Fulton RS, Miller CA, Duncavage EJ, Schroeder MA, Ghobadi A, Pusic I, Stockerl-Goldstein KE, Kahl BS, Cashen AF, Christopher MJ, Singh N, Vij R, Crees ZD, Wartman LD, Day RB, Fehniger TA, Oetjen KA, Patel DA, Kim MY, Slade MJ, Ferraro F, Walter MJ, Abboud CN, Abboud R, Link DC, Al-Mansour ZA, Cogle CR, Huselton EJ, DiPersio JF, Westervelt P, Ley TJ.   +38 more
europepmc   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba, Mark Shacker, Timothy P. Fleming, Michael A. Smith, Ross M. Bremner, Narendra V. Sankpal   +5 more
wiley   +1 more source

Beyond Biochemical Clearance: Linking Immunosuppressive Bile-Acid Removal to Host Defense and Clinical Outcomes in Severe Liver Failure. [PDF]

Crit Care Explor
Kalal CR, Gupta P.
europepmc   +1 more source

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

Molecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir, Elena Haro‐Martínez, Sandra Blasco‐Benito, Chiara Cannatà, José Ángel Palomeque, Anna López‐Plana, Maria Sanz‐Flores, Marc Sabartés, Cristina Fornaguera, Toni Celià‐Terrassa   +9 more
wiley   +1 more source

Artificial Intelligence-Based Prediction of Pancreatic Stone Clearance in Pancreatolithiasis Using Pretreatment CT Images and Clinical Features. [PDF]

Diagnostics (Basel)
Yamamoto S, Teramoto A, Ono T, Hashimoto S, Katano Y, Kobayashi T, Muto H, Tachi Y, Miyoshi H, Inui K.   +9 more
europepmc   +1 more source